Maksim A. Aleksandrovich Klimenko

Mr. Maksim A. Aleksandrovich Klimenko


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
MSMaria Sokol
Maria Sokol
IGIvan Gulyaev
Ivan Gulyaev
MCMargarita Chirkina
Margarita Chirkina
MKMaksim A. Aleksandrovich Klimenko
Maksim A. Aleksandrovich Klimenko
OKOlga Kamaeva
Olga Kamaeva
Elena Dmitrievna NikolskayaElena Dmitrievna Nikolskaya
Elena Dmitrievna Nikolskaya
The modern livestock industry incorporates widely used antibiotic growth promoters into animal feed at sub-therapeutic levels to enhance growth performance and feed efficiency. However, this practice contributes to the emergence of antibiotic-resistant pathogens in livestock, which may be transmitted to humans through the food chain, thereby diminishing the efficacy of antibiotics in treating bacterial infections. Current research explores the potential of essential oils from derived medicinal plants as alternative phytobiotics. This review examines modern encapsulation strategies that incorporate essential oils into natural-origin matrices to improve their stability and control their release both in vitro and in vivo. We discuss a range of encapsulation approaches utilizing polysaccharides, gums, proteins, and lipid-based carriers. This review highlights the increasing demand for antibiotic alternatives in animal nutrition driven by regulatory restrictions, and the potential benefits of essential oils in enhancing feed palatability and stabilizing the intestinal microbiome in monogastric animals and ruminants. Additionally, we address the economic viability and encapsulation efficiency of different matrix formulations.

16 July 2025 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MMMariia Romanovna Mollaeva
Mariia Romanovna Mollaeva
Nikita G YabbarovNikita G Yabbarov
Nikita G Yabbarov
MSMaria Sokol
Maria Sokol
MCMargarita Chirkina
Margarita Chirkina
IGIvan Gulyaev
Ivan Gulyaev
Elena Dmitrievna NikolskayaElena Dmitrievna Nikolskaya
Elena Dmitrievna Nikolskaya

Verified
Journal Article
Open access
PDF file
MKMaksim A. Aleksandrovich Klimenko
Maksim A. Aleksandrovich Klimenko
MSMaria Sokol
Maria Sokol
MMMariia Romanovna Mollaeva
Mariia Romanovna Mollaeva
Nikita G YabbarovNikita G Yabbarov
Nikita G Yabbarov
IGIvan A. Gulyaev
Ivan A. Gulyaev
Elena Dmitrievna NikolskayaElena Dmitrievna Nikolskaya
Elena Dmitrievna Nikolskaya
Poly(lactic-co-glycolic) acid nanoparticles (NPs) with the addition of the sodium salt of cobalt bis(1,2-dicarbollide) (COSAN) were developed for boron neutron capture therapy (BNCT). The Box–Behnken design was applied to predict an optimal value of variables and to obtain the desired NP characteristics. The optimized NPs had a size of 166 nm and a COSAN loading of 16%. Based on FTIR and UV-VIS spectrophotometry data, it was found that COSAN maintains chemical stability during the encapsulation process and exhibits prolonged release from NPs. A study of in vitro cytotoxicity and accumulation of the NPs on B16 cells revealed their low toxicity and high accumulation in cells after 24 h. In vivo analysis in B16-bearing BALB/c nude mice showed preliminary tumor-associated 10B distribution 12 h after iv administration of a deliberately low NP-CPPC dose (50 µg per mouse). The estimated intratumoral concentration was 0.31 µg 10B/g, which is below commonly cited BNCT delivery benchmarks. These results show high potential of the formulation, but require further optimization of dose, timing, biodistribution, normal-tissue exposure, tolerability and therapeutic-dose BNCT evaluation.